Choroidal Neovascularization - Pipeline Review, H1 2018

March 2018 | 47 pages | ID: C1DBBFB8A7CEN
Global Markets Direct

Abstracts

Choroidal Neovascularization - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Choroidal Neovascularization - Pipeline Review, H1 2018, provides an overview of the Choroidal Neovascularization (Ophthalmology) pipeline landscape.

Choroidal neovascularization (CNV) involves the growth of new blood vessels that originate from the choroid Symptoms include painless loss of vision, metamorphopsia, and color disturbances. Treatment includes ant-VEGF agents, laser photocoagulation and photodynamic therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Choroidal Neovascularization - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Choroidal Neovascularization (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Choroidal Neovascularization (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Choroidal Neovascularization and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Choroidal Neovascularization (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Choroidal Neovascularization (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Choroidal Neovascularization (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Choroidal Neovascularization (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Choroidal Neovascularization (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Choroidal Neovascularization (Ophthalmology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Choroidal Neovascularization (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Choroidal Neovascularization (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Choroidal Neovascularization - Overview
Choroidal Neovascularization - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Choroidal Neovascularization - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Choroidal Neovascularization - Companies Involved in Therapeutics Development
F. Hoffmann-La Roche Ltd
Formycon AG
Iconic Therapeutics Inc
Isarna Therapeutics GmbH
Lupin Ltd
Mabion SA
NovelMed Therapeutics Inc
Noxxon Pharma AG
Promedior Inc
Choroidal Neovascularization - Drug Profiles
ACX-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides for Ophthalmology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ayuv-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Calreticulin for Choroidal Neovascularization - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICON-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-0036 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NM-9405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOXD-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRM-167 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-7716 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Inflammation and Choroidal Neovascularization - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Age Related Macular Degeneration and Choroidal Neovascularization - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Choroidal Neovascularization - Dormant Projects
Choroidal Neovascularization - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Choroidal Neovascularization, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Choroidal Neovascularization - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Choroidal Neovascularization - Pipeline by Formycon AG, H1 2018
Choroidal Neovascularization - Pipeline by Iconic Therapeutics Inc, H1 2018
Choroidal Neovascularization - Pipeline by Isarna Therapeutics GmbH, H1 2018
Choroidal Neovascularization - Pipeline by Lupin Ltd, H1 2018
Choroidal Neovascularization - Pipeline by Mabion SA, H1 2018
Choroidal Neovascularization - Pipeline by NovelMed Therapeutics Inc, H1 2018
Choroidal Neovascularization - Pipeline by Noxxon Pharma AG, H1 2018
Choroidal Neovascularization - Pipeline by Promedior Inc, H1 2018
Choroidal Neovascularization - Dormant Projects, H1 2018
Choroidal Neovascularization - Dormant Projects, H1 2018 (Contd..1), H1 2018
Choroidal Neovascularization - Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development for Choroidal Neovascularization, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

F. Hoffmann-La Roche Ltd
Formycon AG
Iconic Therapeutics Inc
Isarna Therapeutics GmbH
Lupin Ltd
Mabion SA
NovelMed Therapeutics Inc
Noxxon Pharma AG
Promedior Inc